Tenapanor administration and the activity of the H+‐coupled transporter PepT1 in healthy volunteers
Open Access
- 22 April 2017
- journal article
- drug interactions
- Published by Wiley in British Journal of Clinical Pharmacology
- Vol. 83 (9) , 2008-2014
Abstract
Aim: Tenapanor (RDX5791/AZD1722), an inhibitor of gastrointestinal Na+/H+ exchanger NHE3, is being evaluated for the treatment of patients with constipation‐predominant irritable bowel syndrome and the treatment of hyperphosphataemia in patients with chronic kidney disease on dialysis. By reducing intestinal H+ secretion, inhibition of NHE3 by tenapanor could indirectly affect H+‐coupled transporter activity, leading to drug–drug interactions. We investigated the effect of tenapanor on the activity of the H+‐coupled peptide transporter PepT1 via assessment of the pharmacokinetics of cefadroxil – a compound transported by PepT1 – in healthy volunteers.Methods: In this open‐label, two‐period crossover, phase 1 study (NCT02140281), 28 volunteers received in random order: a single dose of cefadroxil 500 mg for 1 day; and tenapanor 15 mg twice daily over 4 days followed by single doses of both cefadroxil 500 mg and tenapanor 15 mg on day 5. There was a 4‐day washout between treatment periods.Results: Cefadroxil exposure was similar when administered alone or in combination with tenapanor {geometric least‐squares mean ratios [(cefadroxil + tenapanor)/cefadroxil] (90% confidence interval): area under the concentration–time curve 93.3 (90.6–96.0)%; maximum concentration in plasma 95.9 (89.8–103)%}. Tenapanor treatment caused a softening of stool consistency and an increase in stool frequency, consistent with its expected pharmacodynamic effect. No safety concerns were identified and tenapanor was not detected in plasma.Conclusions: These results suggest that tenapanor 15 mg twice daily does not have a clinically relevant impact on the activity of the H+‐coupled transporter PepT1 in humans. This may guide future research on drug–drug interactions involving NHE3 inhibitors.Keywords
Funding Information
- AstraZeneca
This publication has 31 references indexed in Scilit:
- The epithelial sodium/proton exchanger, NHE3, is necessary for renal and intestinal calcium (re)absorptionAmerican Journal of Physiology-Renal Physiology, 2012
- Hijacking Solute Carriers for Proton-Coupled Drug TransportPhysiology, 2010
- Transport of drugs by proton-coupled peptide transporters: pearls and pitfallsExpert Opinion on Drug Metabolism & Toxicology, 2009
- Pharmaceutical and pharmacological importance of peptide transportersJournal of Pharmacy and Pharmacology, 2008
- H+-coupled nutrient, micronutrient and drug transporters in the mammalian small intestineExperimental Physiology, 2007
- Optimal absorptive transport of the dipeptide glycylsarcosine is dependent on functional Na + /H + exchange activityPflügers Archiv - European Journal of Physiology, 2002
- Stool Form Scale as a Useful Guide to Intestinal Transit TimeScandinavian Journal of Gastroenterology, 1997
- Effects of aging on the microclimate pH of the rat jejunumBiochimica et Biophysica Acta (BBA) - Biomembranes, 1996
- Na+-dependent elevation of the acidic cell surface pH (microclimate pH) of rat jejunal villus cells induced by cyclic nucleotides and phorbol ester: possible mediators of the regulation of the Na+/H+ antiporterBiochimica et Biophysica Acta (BBA) - Biomembranes, 1988
- Effects of Potential Damaging Agents on the Microclimate-pH in the Rat JejunumJournal of Pharmaceutical Sciences, 1986